Introduction
============

More than 50 years after its introduction by George C. Cotzias ([@awu195-B11]), levodopa still is the most effective treatment for the motor symptoms of Parkinson's disease. In studies including patients in the pre-levodopa era, early treatment with levodopa proved to increase life expectancy ([@awu195-B17]). However, long-term management of patients on chronic levodopa is hampered by the occurrence of motor fluctuations and dyskinesias which, as the disease progresses, usually become major causes of disability and reduced quality of life ([@awu195-B8]). To date, the pathophysiological mechanisms underlying the occurrence of levodopa-induced complications are still poorly understood.

In animal studies, the occurrence of motor fluctuations and dyskinesias has been associated with the extent of nigral neuronal loss and with the duration and dose of levodopa therapy, as independent factors ([@awu195-B5]; [@awu195-B26]; [@awu195-B33]). Motor complications have been described to occur very early after the initiation of levodopa therapy in monkeys and humans with MPTP-induced parkinsonism, who display rapid and severe depletion of dopaminergic neurons ([@awu195-B63]; [@awu195-B3]). However, current experimental models of levodopa-induced motor complications cannot replicate the pathophysiological changes that occur during the progressive neurodegenerative process of idiopathic Parkinson's disease, mainly due to the rapid and extensive nigral denervation. Thus, the issue of the relationship between levodopa and motor complications should be addressed by clinical studies in patients with Parkinson's disease. A number of large drug trials reported that the initial treatment with a dopamine agonist was associated with a lower incidence of motor complications than initial treatment with levodopa ([@awu195-B52]; [@awu195-B55]; [@awu195-B23]; reviewed in [@awu195-B59]). Likewise, higher rates of dyskinesias were reported in association with higher cumulative doses of levodopa ([@awu195-B27]; [@awu195-B50]) and longer duration of levodopa treatment ([@awu195-B45]; [@awu195-B25]; [@awu195-B56]). Overall, these observations led clinicians to consider levodopa therapy as an additional source of disability within the natural history of Parkinson's disease ([@awu195-B53]) and supported the clinical practice of delaying the initiation of levodopa therapy as long as possible to reduce the risk of motor complications ([@awu195-B22], [@awu195-B24]; [@awu195-B35]). The ELLDOPA study was specifically designed to provide conclusive evidence as to whether levodopa could be safely initiated early or should be delayed in newly diagnosed patients with Parkinson's disease ([@awu195-B22]). The ELLDOPA study was specifically designed to provide conclusive evidence as to whether levodopa could be safely initiated early or should be delayed in newly diagnosed patients with Parkinson's disease ([@awu195-B22]). Unfortunately, although the ELLDOPA study did not find any clinical or imaging evidence indicating that early use of levodopa could negatively impact the course of the disease ([@awu195-B23]), it failed to change the patterns of treatment of Parkinson's disease (as neurologists remained concerned about levodopa's likelihood to induce motor complications) ([@awu195-B24]). Therefore, the question as to whether the risk of levodopa-induced motor complications is primarily associated with levodopa therapy or disease progression itself remained unanswered.

Theoretically, the differences between the effects of treatment-related variables (i.e. levodopa therapy duration versus daily dose) and the effects of disease progression (i.e. disease duration versus severity) in promoting motor complications without confounders (such as concomitant dopamine agonist therapy) could be conclusively demonstrated only by a trial including patients with Parkinson's disease left untreated for several years after onset of disease and then followed-up after the initiation of levodopa. Obviously, such a study design is not ethically acceptable. Early motor complications have been described in series including patients from the pre-levodopa era, who had longer disease duration at the initiation of levodopa therapy ([@awu195-B1]). However, the exact relationship between disease-related variables and levodopa dose could not be established, because of the tendency towards more aggressive levodopa dosing (due to the initial lack of DOPA decarboxylase inhibitors), and the lack of systematic assessment of motor fluctuation rates ([@awu195-B1]) and of motor symptom severity using validated rating tools \[e.g. the Unified Parkinson's Disease Rating Scale (UPDRS); [@awu195-B23]; [@awu195-B53]\]. In sub-Saharan African countries, the access to medication is limited and the initiation of levodopa therapy often occurs several years after the onset of motor symptoms ([@awu195-B9]; [@awu195-B18]), closely resembling what is described in series containing patients with Parkinson's disease from the pre-levodopa era ([@awu195-B1]). In this scenario, we conducted a 4-year naturalistic study investigating a large cohort of patients with Parkinson's disease from a sub-Saharan African country (Ghana), whose primary objective was to disentangle the relative role played by treatment-related variables and disease progression *per se* in the pathophysiology of motor complications.

Materials and methods
=====================

Participants
------------

All subjects consecutively attending three out-patient clinics in different regions of Ghana between December 2008 and November 2012 were examined and screened for any movement disorder by local neurologists (A.A., F.S.S.) or by a medical officer (M.C.). Parkinsonism was suspected by the local clinician on the basis of the presence of at least three of the four cardinal features (i.e. resting tremor, rigidity, bradykinesia, and postural or gait abnormality). Patients were then assessed in consecutive order by a neurologist specialized in movement disorders (R.C.) and by another movement disorder specialist (M.A., M.F., G.P.), who made the diagnosis according to current criteria ([@awu195-B30]; [@awu195-B39]). In case of any doubt or disagreement between the investigators, the patient was admitted to hospital for in-depth clinical evaluation and additional investigation (e.g. neuroimaging). Onset of the disease was defined at the first appearance of any motor symptom, as reported by the patient, a family member or a clinician. In case of any doubt or uncertainty, we adopted a recall technique tailored to major events in the patient's life. Considering the relatively high average number of offspring and grandchildren, we used information on offspring to investigate the relationship between the year of onset and either major preschool milestones of development of grandchildren (e.g. birth, first unassisted steps) or other meaningful events in the family (e.g. wedding of offspring). Early onset was defined as age at onset ≤50 years. Family history for Parkinson's disease was limited to first-degree relatives.

Clinical work-up included the UPDRS from part I to part IV ([@awu195-B21]) and Hoehn and Yahr (HY) staging ([@awu195-B28]). Major milestones of disease progression were assessed using the UPDRS items of part I (psychosis, item 2 score ≥ 2; depression or apathy, sum of items 3 + 4 ≥ 4), part II (dysphagia, item 7 score ≥ 2; falls, item 13 score ≥ 2) and part III (postural instability, item 30 score ≥ 2) (as described in [@awu195-B44]). Dementia was diagnosed according to the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria ([@awu195-B2]). Motor phenotype at disease presentation was assessed in the 'OFF' state ([@awu195-B32]). Acute levodopa challenge was performed using dispersible levodopa/benserazide 100 mg + 50 mg, giving either a 150-mg or 200-mg levodopa dose, according to body weight (≤ or \>70 kg, respectively); all patients were assessed after 12-h medication withdrawal (OFF state) and 90 min after levodopa intake (ON state). In drug-naïve patients, levodopa therapy was initiated immediately, starting from 50 mg once daily and slowly titrating up to 100 mg three times daily, 20--30 min before meals. If further treatment was required, an additional 50 or 100 mg of levodopa could be added to each of the doses, as appropriate, to achieve adequate control of motor symptoms. At each visit, the presence of motor fluctuations and dyskinesias was assessed by recall and prolonged direct observation, and time of their first occurrence was recorded. Patients were observed for a minimum of 4 h after the administration of dispersible levodopa/benserazide to monitor motor response. In case of uncertainty about either the response to levodopa therapy or the presence of motor fluctuations or dyskinesias, patients were admitted to hospital. Motor fluctuations were defined as predictable wearing-off, unpredictable ON--OFF fluctuations and sudden OFF periods according to UPDRS part IV ([@awu195-B21]). Dyskinesias were defined as abnormal involuntary movements, including chorea and dystonia, that could be peak dose or diphasic; OFF-related dystonia was not included. In-between the follow-up visits by the principal investigator, local doctors visited all patients every 2 months to review therapy tolerability, onset of motor complications, and to provide levodopa supplies free of charge ([@awu195-B9]). Follow-up visits were performed by the principal investigator every 6 months during the study period.

A large cohort of consecutive patients with Parkinson's disease (*n =*2282) assessed for the first time at the Parkinson Institute in Milan during the same 4-year period was considered as control group for demographic and general clinical features. During this period, a total of nine neurologists examined on average three new patients every work week (of whom 42--48% were diagnosed as probable idiopathic Parkinson's disease) for a total of 46 weeks in a year. Nested matched subgroups were then used to investigate the frequency and severity of major motor and non-motor symptoms, including the relationship between levodopa therapy and the onset of motor complications.

Ethics
------

The study was performed in agreement with the principles of the Declaration of Helsinki and the protocol was approved by the local Ethics Committee. We obtained written informed consent from every patient; an additional consent was requested for video recording. Informed consent was translated into local Ghanaian dialect whenever required and/or it was provided by a first-degree relative in cases with clinical dementia.

Statistical analysis
--------------------

Data were analysed using the software program SPSS (Windows Release 17.0; SPSS Inc.). We conducted a cross-sectional data analysis and a prospective cohort study. A two-sided *P*-value of \<0.05 was set as significant. A flow diagram of study analyses is provided as [Fig. 1](#awu195-F1){ref-type="fig"}. Figure 1Flow diagram of study analyses. Abbreviations: DA-A, dopamine agonists; iCOMT, Catechol-O-Methyltransferase inhibitors; PD, Parkinson s disease; PKS, parkinsonism.

### Cross-sectional data analysis

Demographic features were initially compared with those of the whole control Italian Parkinson's disease population consecutively recruited during the same 4-year period. In the second instance, we used a subgroup of Parkinson's disease control subjects matched 1:2 for gender, age and disease duration at the first assessment. Finally, to minimize the obvious bias associated with the difference in drug availability between the two countries, we performed an additional analysis after matching also for therapy regimen. Descriptive statistics were provided for continuous \[mean and standard deviation (SD) or median and interquartile range (IQR, 25th--75th percentile)\] and categorical (count and percentage) variables. Two-group comparisons were performed using Fisher's exact test (categorical variables) and Student's *t*-test or Mann-Whitney U-test (continuous variables), as appropriate. When the analyses included multiple groups and *post hoc* comparisons, differences in clinical features were analysed with ANOVA or the χ^2^ test as appropriate. *Post hoc* comparison of means was performed using Scheffe's test.

Finally, the risk of developing wearing-off and dyskinesias was computed as odd ratio (OR) and 95% confidence interval (95% CI) using multivariable logistic regression analysis including non-collinear variables (identified from the literature and based on consensus among the authors) showing an association at univariate analysis.

### Prospective data analysis

All patients examined by the principle investigator at least twice ≥6 months apart at any of the three clinics were included in the longitudinal analysis. Time-course comparisons of paired datasets were performed by using Wilcoxon's (continuous variables) or McNemar's (categorical variables) test.

Results
=======

Whole cohort of patients with any parkinsonian syndrome
-------------------------------------------------------

During the period between December 2008 and November 2012, a total of 101 patients presenting with any Parkinsonism were identified at the three Ghanaian clinics (males, *n =*64; age at onset, 60.8 ± 11.7 years; OFF-state UPDRS III, 35.1 ± 14.7) and subsequently underwent neurological examination by the Italian team of movement disorders specialists. Among those with a probable degenerative aetiology, 91 fulfilled diagnostic criteria for idiopathic Parkinson's disease and two for progressive supranuclear palsy. Neuroimaging was available for 26 of 101 cases (CT, *n =*22; MRI, *n =*4); of these, 21 were diagnosed as having Parkinson's disease, three had vascular parkinsonism, one had extensive calcinosis of basal ganglia and cerebellar nuclei, and another had young-onset rapid-progressing parkinsonism of unknown aetiology. Brain imaging of patients with Parkinson's disease was either normal (*n =*14/21) or showed mild-to-moderate cortical atrophy (*n =*7/21) with concomitant mild chronic small-vessel disease in three cases.

Idiopathic Parkinson's disease
------------------------------

### Cross-sectional analysis

Ghanaian patients with Parkinson's disease and Italian consecutive control patients had similar demographic features, including age at onset ([Table 1](#awu195-T1){ref-type="table"}). Nineteen of 91 patients with Parkinson's disease (20.9%) had early onset. Positive family history was reported in eight patients with early-onset and 11 with late-onset Parkinson's disease. Table 1Cross-sectional analysis of demographic and general clinical features of Ghanaian patients with Parkinson's disease at the baseline visit compared to all consecutive Italian patients with Parkinson's disease examined for the first time during the same 4-year study period**FeaturesGhanaian Parkinson's diseaseItalian Parkinson's disease*P*-value**(*n =*91)(*n =*2282)Males *n* (%)58 (63.7)1291 (56.6)0.196Age at onset, mean (SD) \[range\], y60.6 (11.3) \[27--91\]62.0 (10.7) \[20--89\]0.217Early onset *n* (%)19 (20.9)344 (15.1)0.137Positive family history for Parkinson's disease *n* (%)19 (20.9)[^a^](#awu195-TF1){ref-type="table-fn"}356 (15.6)0.140Right body side of Parkinson's disease onset *n* (%)47 (51.7)1,355 (59.4)0.176Never treated *n* (%)32 (35.2)143 (6.3)**\<0.001**Education, mean (SD), y9.0 (6.3)10.3 (4.5)**0.016**Cigarette smoking *n* (%)6 (6.6)361 (15.8)**\<0.001**[^2]

In case-control analysis, Ghanaian patients with Parkinson's disease presented more frequently with a tremor-dominant phenotype and had longer disease duration at diagnosis and, subsequently, at the initiation of levodopa therapy ([Table 2](#awu195-T2){ref-type="table"}). OFF state disability and severity of motor symptoms at assessment was, overall, comparable between the two groups, with the only exception of higher resting tremor scores in Ghanaians. Likewise, there was no difference in the frequency of major non-motor symptoms and non-levodopa-responsive motor symptoms ([Table 2](#awu195-T2){ref-type="table"}). Table 2Clinical features of Ghanaian patients with Parkinson's disease compared to Italian matched Parkinson's disease controls at the baseline visit**FeaturesGhanaControls*P*-value**[\*](#awu195-TF5){ref-type="table-fn"}(*n =*91)(*n =*182)Males *n* (%)58 (63.7)110 (60.4)0.692[^a^](#awu195-TF2){ref-type="table-fn"}Age at onset, y60.6 (11.3)60.4 (10.9)0.862[^a^](#awu195-TF2){ref-type="table-fn"}Disease duration at diagnosis, mean (SD) \[range\], y3.9 (2.4) \[1--12\]1.1 (1.4) \[0--8\]**\<0.001**Disease duration at levodopa initiation, mean (SD) \[range\], y[^b^](#awu195-TF3){ref-type="table-fn"}4.2 (2.8) \[1--12\]2.4 (2.1) \[0--11\]**\<0.001**Disease duration at assessment, y5.0 (3.0)5.1 (2.9)0.830[^a^](#awu195-TF2){ref-type="table-fn"}Tremor-dominant presenting phenotype *n* (%)68 (74.7)94 (52.2)**\<0.001**UPDRS part I2.2 (2.2)2.0 (1.9)0.616    With dementia *n* (%)9 (9.9)12 (6.6)0.455    With psychosis *n* (%)5 (5.5)7 (3.8)0.527    With depression/apathy *n* (%)13 (14.3)30 (16.5)0.878UPDRS part II -- ON7.0 (4.9)9.5 (5.5)0.110UPDRS part II -- OFF12.4 (7.8)11.4 (6.4)0.256    With dysphagia *n* (%)7 (8.4)30 (16.5)0.09    With falls *n* (%)12 (13.1)31 (17.0)0.484    With freezing of gait *n* (%)12 (13.2)16 (8.8)0.192UPDRS part III -- ON23.5 (11.2)20.4 (10.9)0.115UPDRS part III -- OFF34.9 (15.1)24.9 (10.8)**\<0.001**    Tremor at rest[^c^](#awu195-TF4){ref-type="table-fn"}4.6 (3.6)1.7 (2.1)**0.001**    Axial symptoms[^c^](#awu195-TF4){ref-type="table-fn"}5.4 (4.0)3.9 (2.7)0.268    With postural instability *n* (%)27 (29.7)62 (34.1)0.892Response to acute levodopa challenge, %45.0 (13.1)41.0 (11.6)0.328Hoehn and Yahr stage -- OFF    On Stage I *n* (%)9 (10)29 (16)0.164    On Stage II *n* (%)52 (57)104 (57)    On Stage III *n* (%)21 (23)38(21)    On Stage IV-V *n* (%)9 (10)11 (6)**Therapy**    On chronic levodopa *n* (%)59 (64.8)160 (87.9)**\<0.001**    Levodopa duration at assessment, median \[IQR\], y1.0 \[0--2\]2.5 \[1--5\]**\<0.001**    Levodopa dose, mg/day[^b^](#awu195-TF3){ref-type="table-fn"}365 (154)426 (182)**0.012**    Levodopa dose, mg/kg/day[^b^](#awu195-TF3){ref-type="table-fn"}6.5 (3.2)6.0 (2.2)0.589    On dopamine agonists *n* (%)0 (0)131 (72)**\<0.001**    On anticholinergics *n* (%)28 (30.8)20 (11)**\<0.001**    On amantadine *n* (%)7 (7.7)2 (1.1)**0.007**    On COMT inhibitors *n* (%)0 (0)35 (19.2)**\<0.001**    On MAO-B inhibitor *n* (%)4 (4.4)52 (28.6)**\<0.001**[^3][^4][^5][^6]

The mean disease duration at the baseline assessment was 5 years and ∼35% of Ghanaian patients with Parkinson's disease were drug-naïve, a frequency 4-fold higher than in the control population ([Table 1](#awu195-T1){ref-type="table"}). Although levodopa daily dose was slightly higher in the Italian group, this difference was no longer significant after adjusting for body weight ([Table 2](#awu195-T2){ref-type="table"}). Disease duration at the initiation of levodopa therapy was significantly longer in Ghanaian patients with Parkinson's disease, so that the two cohorts differed according to the duration of levodopa therapy ([Table 2](#awu195-T2){ref-type="table"}). Mean levodopa daily dose adjusted for body weight was similar in the two groups at the time of the baseline assessment. Accordingly, it was reasonable to argue that cumulative exposure to levodopa substantially relied on the duration of treatment. The frequency of motor complications were calculated using the number of patients on chronic levodopa therapy as denominator (*n =*59 for the study population; *n =*160 for the control population, [Table 2](#awu195-T2){ref-type="table"}). After a median time of 1 year since the initiation of levodopa, the frequency of prevalent motor fluctuations and dyskinesias in Ghanaian patients was 56% and 14%, respectively. Motor fluctuations were recorded as wearing-off phenomenon in the majority of patients (*n =*30/33, 90.9%). Median disease duration at the first appearance of motor fluctuations and dyskinesias was comparable between Ghanaians and Italian patients \[6.0 (IQR 5--8) versus 5.5 years (IQR 4--7), *P =*0.149 for motor fluctuations; 7.0 (IQR 6--10.25) versus 6.5 years (IQR 5--8), *P =*0.567 for dyskinesias\], despite significantly shorter median duration of levodopa therapy at their onset in Ghanaians \[0.5 (IQR 0--1) versus 2.0 years (IQR 1--4), *P =*0.001 for motor fluctuations; 1.0 (IQR 0.25--2) versus 3.0 years (IQR 2--5.25), *P =*0.004 for dyskinesias; [Fig. 2](#awu195-F2){ref-type="fig"}A\]. Figure 2(**A**) Relationship between initiation of levodopa therapy and onset of motor fluctuations, and between initiation of levodopa therapy and onset of dyskinesias in Ghanaian patients with Parkinson's disease and Italian Parkinson's disease control subjects with motor fluctuations ([Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awu195/-/DC1)). (**B**) The Parkinson's disease control group has been additionally matched for therapy regimen ([Table 3](#awu195-T3){ref-type="table"}).

However, a large disparity in medication availability and affordability was responsible for the large differences between the two countries in terms of prescription schedule and introduced a bias in the estimation of the frequency of motor complications. In particular, Ghanaians could not benefit from dopamine-agonists and COMT-inhibitors ([Table 2](#awu195-T2){ref-type="table"}), because these drugs are not commonly available in most sub-Saharan African countries due to their high cost. Likewise, they were less exposed to MAO-B inhibitors, whereas anticholinergics and amantadine were more commonly prescribed as first-line therapy because they are cheaper than levodopa ([Table 2](#awu195-T2){ref-type="table"}). Therefore, to minimize confounders of our estimate of motor complications, we used a control group of patients with Parkinson's disease who had never been exposed to any dopamine agonist or COMT inhibitor (defined as 'therapy-matched', [Fig. 1](#awu195-F1){ref-type="fig"} and [Table 3](#awu195-T3){ref-type="table"}). The motor fluctuation rate was similar in the two patient populations, with a slightly lower prevalence of dyskinesias in Ghanaians. Levodopa daily dose was higher in Italians, but this difference was no longer significant after adjusting for body weight. Severity of motor symptoms was similar in terms of UPDRS scores and Hoehn and Yahr stage ([Table 3](#awu195-T3){ref-type="table"}). Again, this analysis confirmed that the disease duration was similar at the onset of motor complications, despite significant differences in the duration of exposure to levodopa ([Fig. 2](#awu195-F2){ref-type="fig"}B). Table 3The relationship between motor complications and therapy features in Ghanaian patients with Parkinson's disease on chronic levodopa compared to a group of Italian Parkinson's disease controls never treated with any dopamine agonist or COMT inhibitor (defined as 'therapy-matched')**General features and therapyGhanaTherapy--matched controls*P-value***^†^(*n =*59)(*n =*50)Males *n* (%)37 (62.7)26 (52)0.450[^a^](#awu195-TF6){ref-type="table-fn"}Age at onset, y60.8 (9.7) \[35--78\]60.8 (8.4) \[29--73\]0.966[^a^](#awu195-TF6){ref-type="table-fn"}Disease duration at levodopa initiation, y4.2 (2.8) \[1--12\]1.8 (1.6) \[0.3--7\]**\<0.001**Disease duration at assessment, y5.8 (3.3) \[1--20\]5.7 (2.9) \[1--12\]0.663[^a^](#awu195-TF6){ref-type="table-fn"}UPDRS part III -- OFF36.8 (15.4) \[7--74\]34.4 (17.9) \[13--69\]0.615UPDRS part III -- ON23.5 (11.2)21.8 (9.4)0.726Hoehn and Yahr stage -- OFF2.6 (0.9) \[1--5\]2.4 (0.7) \[1--5\]0.151Hoehn and Yahr stage -- ON1.9 (0.6) \[1--4\]1.8 (0.6) \[1--4\]0.311Levodopa duration at assessment, median \[IQR\], y1.0 \[0--2\]4.0 \[2--6\]**\<0.001**Levodopa dose, mg/day365 (154) \[100--750\]496 (227) \[150--1050\]**0.002**    Levodopa dose, mg/kg/day6.5 (3.2) \[2--17\]7.0 (3.2) \[1.9--17.2\]0.473    Body weight, kg62.9 (13.7) \[37--93\]71.5 (14.1) \[48--102\]**0.006**    Body mass index, kg/m^2^22.4 (3.9) \[15.8--30.5\]26.3 (4.1) \[16.6--36\]**0.003Motor complications**Motor fluctuations *n* (%)33 (55.9)28 (56)0.931Disease duration at onset of motor fluctuations, median \[IQR\], y6.0 \[5--8\]5.5 \[4--6\]0.134Levodopa duration at onset of motor fluctuations, median \[IQR\], y0.5 \[0--1\]4.5 \[3--5\]**\<0.001**Dyskinesias *n* (%)8 (13.6)17 (34)**0.013**Disease duration at onset of dyskinesias, median \[IQR\], y7.0 \[6--10.25\]6.0 \[4--7\]0.227Levodopa duration at onset of dyskinesias, median \[IQR\], y1.0 \[0.25--2\]5.0 \[4--6\]**0.003Non--FluctuatorsFluctuatorsNon-FluctuatorsFluctuators*P-value*^‡^**(*n =*26)(*n =*33)(*n =*22)(*n =*28)Age at onset, y61.6 (8.8)59.4 (9.7)630.5 (50.3)**^§^**58.6 (9.7)**0.044**Disease duration at levodopa initiation, y3.4 (2.0)**^§§^**5.9 (2.6)^\#\#^10.9 (10.8)1.6 (1.4)**0.002**Disease duration at Assessment, y4.5 (2.0)6.3 (3.0)40.2 (20.9)6.8 (2.4)0.098UPDRS part III - OFF32.6 (12.0)**^§^**41.3 (16.2)^\#\#^220.0 (90.7)**^§§^**30.8 (11.8)**\<0.001**Hoehn and Yahr stage - OFF2.3 (0.9)2.7 (0.9)20.0 (00.3)**^§§^**2.6 (0.7)**0.004**Levodopa Ddose, median \[IQR\], mg/day300 \[300--400\]300 \[300--450\]^\#\#^300 \[300--4310.25\]**^§^**600 \[400--775\]**0.008**Levodopa dose weight-adjusted, median \[IQR\], mg/kg/day5.0 \[4.4--5.6\]6.0 \[4.8--8\]^\#^40.7 \[40.1--60.35\]**^§§^**7.8 \[6.2--10.25\]**0.004**[^7][^8][^9]

According to ANOVA, age at Parkinson's disease onset was lower in Italian control patients with motor fluctuations than in those without, whereas Hoehn and Yahr stage and median levodopa dose (including weight-adjusted) were higher. These features did not differ in Ghanaians. OFF-state UPDRS III scores were higher in patients with Parkinson's disease with motor fluctuations (defined as 'fluctuators') than in those without (defined as 'non-fluctuators') in both groups ([Table 3](#awu195-T3){ref-type="table"}). The subgroups of 'fluctuators' included all patients who developed dyskinesias. Ghanaian patients who developed dyskinesias were younger at onset than those who did not \[median 55.6 (IQR 51.5--58) versus 63.1 (IQR 58--68.5), *P =*0.011\]. In Ghana, neither males nor females showed any significant difference relating to the severity of motor symptoms, the time from onset to the initiation of levodopa, and the frequency of motor fluctuations and dyskinesias controlled for weight-adjusted levodopa dose (data not shown).

Finally, logistic regression analysis confirmed that wearing-off and dyskinesias were associated with disease duration and levodopa daily dose, but not with the duration of levodopa therapy ([Table 4](#awu195-T4){ref-type="table"}). A correct classification of motor fluctuations and dyskinesias was possible in 77% and 79% of patients, respectively, as quantified by the area under the receiver operating characteristic curve (AUC). This set of variables predicted motor fluctuations and dyskinesias better than the model including disease severity. Table 4Logistic regression analysis for predictors of motor complicationsModel prediction (AUC)[**^a^**](#awu195-TF8){ref-type="table-fn"}**Set of variables**[**^b^**](#awu195-TF9){ref-type="table-fn"}**^,^[^c^](#awu195-TF10){ref-type="table-fn"}Motor fluctuationsDyskinesias**A + B + C0.77[^d^](#awu195-TF11){ref-type="table-fn"}0.79[^e^](#awu195-TF11){ref-type="table-fn"}B + C + D0.710.75**Model for motor fluctuations**[^d^](#awu195-TF11){ref-type="table-fn"}**OR (95%CI)*P*-value**Levodopa dose (mg/kg)1.33 (1.05--1.68)**0.019**Duration of levodopa at occurrence (years)1.09 (0.80--1.48)0.606Disease duration at onset of motor fluctuations (years)1.36 (1.01--1.83)**0.040Model for dyskinesias[^e^](#awu195-TF11){ref-type="table-fn"}**Levodopa dose (mg/kg)1.19 (1.00--1.42)**0.045**Duration of levodopa at occurrence (years)0.93 (0.73--1.18)0.550Disease duration at onset of motor fluctuations (years)1.42 (1.07--1.87)**0.014**[^10][^11][^12][^13]

As paradigmatic case, we describe a 61-year-old female with a 6-year Parkinson's disease duration and relatively mild motor symptoms (UPDRS III 19/108), who had peak-dose dyskinesias 60 min after her first-ever levodopa dose (150 mg, 2.2 mg/kg; [Supplemantary Video Segment 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awu195/-/DC1)).

### Longitudinal analysis

Thirty-two patients with Parkinson's disease were included in the longitudinal analysis ([Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awu195/-/DC1)). Of these, 21 were drug-naïve at baseline (65.6%), whereas the remaining 11 patients had started levodopa therapy before our first examination*.* During the follow-up, medical therapy was optimized, leading to an overall improvement in motor disability and activities of daily living. Wearing-off and dyskinesias were effectively managed by adjusting the levodopa dosing regimen in the majority of patients. At the last follow-up all patients were on levodopa, and motor fluctuations and dyskinesias had occurred in 56% and 22% of cases, respectively.

After a mean follow-up of 2.6 years, starting from the initiation of levodopa therapy, 10 of 21 (48%) patients who were drug-naïve at baseline had incident wearing-off and 3/21 (14%) developed dyskinesias. Median disease duration at the time of initiation of levodopa was slightly \>4 years. In agreement with cross-sectional findings, wearing-off and dyskinesias appeared very early, after a median levodopa duration of 6 months and at a median disease duration of 7 years (IQR, 4.3--9).

As paradigmatic case, we describe a 69-year-old patient with Parkinson's disease with a 12-year history of untreated disease and severe motor disability, who developed wearing-off phenomena 24 h after the introduction of levodopa (each levodopa dose lasted \<3 h), whereas peak-dose dyskinesias took 4--5 weeks to appear; levodopa dose was 150 mg four times/day (6.5 mg/kg/day) ([Supplementary Video Segment 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awu195/-/DC1)).

Discussion
==========

In the present 4-year naturalistic study, we had the unique opportunity to observe the effects of chronic levodopa therapy on a large sample of patients with Parkinson's disease untreated for years and produced compelling evidence that the duration of levodopa therapy itself is not a risk factor for the occurrence of 'levodopa-induced' motor complications. The results were consistently provided by a cross-sectional analysis of data collected at the baseline assessment and further supported by the subsequent prospective follow-up of a subgroup of newly diagnosed, untreated patients with Parkinson's disease. In the first part of the study, we showed that the onset of motor complications occurred at comparable disease duration in the two populations, despite the large difference in the duration of exposure to levodopa. In line with data from community-based studies ([@awu195-B56]; [@awu195-B19]), motor fluctuations and dyskinesias occurred after a mean of 6 to 7 years from onset regardless of the timing of initiation of adequate levodopa therapy. Since the 1980s, there has been much debate about whether levodopa could be safely started early or late in the course of the disease ([@awu195-B22], [@awu195-B24]). A number of studies suggested that dyskinesias could be best predicted by high daily levodopa dose ([@awu195-B23]) and longer duration of levodopa treatment ([@awu195-B45]; [@awu195-B56]) and that delaying the initiation of levodopa was the best therapeutic strategy to prevent motor fluctuations and dyskinesias ([@awu195-B20]; [@awu195-B42]; [@awu195-B22]; [@awu195-B46]; [@awu195-B55]; [@awu195-B23]). This induced neurologists to withhold the introduction of adequate levodopa therapy as long as possible (especially in younger patients) and patients to avoid it, generating a sort of widespread 'levodopa phobia' ([@awu195-B37]). However, whether the delay of onset of motor complications in patients initially treated with a dopamine agonist was primarily due to delaying levodopa or rather to the lower levodopa dose needed to compensate motor symptoms remained unclear. The putative protective role of delayed levodopa was challenged by *post hoc* analyses of the CALM-PD trial ([@awu195-B52]), which revealed that the incidence of dyskinesias after initiating levodopa was independent of the initial treatment, after adjusting for disease duration and levodopa daily dose ([@awu195-B14]). Cumulative levodopa dose has been suggested to be an independent predictor of dyskinesias in patients with Parkinson's disease ([@awu195-B27]). However, whether this is primarily related to the duration of treatment or to the daily dose remained unclear. In an experimental study in 6-hydroxydopamine-lesioned rats, animals treated with higher levodopa doses for a short period developed dyskinesias earlier than rats treated chronically with lower doses and exposed to higher cumulative doses ([@awu195-B62]). Taken as a whole, these findings are in line with our data and further support the hypothesis that the timing of initiation of levodopa therapy does not modulate the risk of motor complications. Accordingly, the main variables we need to focus on are individual daily levodopa dose and disease progression itself.

After a mean of 6 years from onset of motor symptoms, the rates of motor fluctuations and dyskinesias in Ghanaian patients on chronic levodopa therapy were 56% and 14%, respectively. Considerable variability in motor complication rates has been reported in literature so far, due to important differences in the population assessed, in levodopa dosage, in time from onset to the initiation of levodopa, and in disease duration and severity at assessment ([@awu195-B56]; [@awu195-B27]; [@awu195-B59]). The motor complication rates in series containing patients from the pre-levodopa era are similar to those found in Ghana after a comparable interval from onset to the initiation of levodopa (58% versus 56% of the present study; [@awu195-B1]). On the other hand, series containing pre-levodopa era patients reported a considerably higher frequency of early dyskinesias compared to the modern era series and to our 'modern pre-levodopa era' study, as ∼50% of patients developed dyskinesias after a median time of 6 months since the initiation of chronic levodopa therapy ([@awu195-B1]). [@awu195-B12] were the first who reported the early appearance of involuntary movements after the initiation of levodopa therapy in 50% of patients with Parkinsonism, describing them as 'dose dependent in each case'. However, in contrast to the present study, patients from the pre-levodopa era had considerably longer median disease duration at introduction of levodopa (6--10 years versus 4 years of the present study) and there was the bias of more aggressive levodopa dosing (reviewed in [@awu195-B1]; [@awu195-B24]). Therefore, it was not possible to disentangle the long duration of the disease from the very high levodopa daily dose and establish which was the most relevant factor for the early development of dyskinesias. Similarly, early motor complications in patients with longstanding and untreated Parkinson's disease have been described even in the modern era in association with high individual levodopa daily doses ([@awu195-B51]).

In agreement with the modern-era literature, our multivariate analysis confirmed that the individual levodopa dosing regimen is a major risk factor for motor fluctuations and dyskinesias ([@awu195-B58]; [@awu195-B50]). Despite the collinearity between levodopa daily dose and disease severity, the early appearance of motor complications was not associated with levodopa overdosing in the Ghanaian cohort, as levodopa was slowly titrated up and kept at a relatively low dose. In particular, mean levodopa daily dose was slightly lower than the recommended initial target dose considered to be the threshold for dyskinesias in the *post hoc* analysis of the STRIDE-PD study (365 mg daily of the present study versus 400 mg daily in [@awu195-B50]). This is even more evident when we consider that Ghanaian patients had longer disease duration at the initiation of levodopa (4 versus 2 years, respectively) and that none of them had concomitant dopamine agonist therapy compared to the majority of patients from the drug trial (∼60% in [@awu195-B50]), thus unbalancing individual levodopa-equivalent daily dose even further. Overall, we believe that the primary cause for the early appearance of motor complications in the Ghanaian Parkinson's disease population was disease progression rather than the relatively high levodopa daily dose. This hypothesis is further supported by a recent imaging study showing that identical doses of levodopa induced increasingly larger changes in striatal dopamine levels as the duration of motor symptoms increased, due to a compensatory mechanism secondary to the reduction in buffering capacity and presynaptic reuptake of dopamine that occurs as Parkinson's disease progresses ([@awu195-B15]). In line with our clinical data, the authors concluded that the primary cause of peak-dose dyskinesias was disease progression and not levodopa *per se* ([@awu195-B15]).

Hence, it seems that we should emphasize the role of substantia nigra pars compacta neuronal loss and the subsequent synaptic dopamine depletion rather than levodopa therapy *per se* to shed light on the pathophysiology of 'levodopa-induced' motor complications. According to presynaptic models of levodopa-induced dyskinesias, the extent of dopamine denervation and striatal dopamine reduction increases the sensitivity of post synaptic receptors and the downstream signalling pathway ([@awu195-B6]), and regulates the level and duration of exposure to levodopa that is required to induce dyskinesias ([@awu195-B33]). From a clinical perspective, it is generally assumed that the severity of motor symptoms reflects the extent of nigrostriatal neuronal loss. In contrast with experimental studies, however, we did not observe a strong association between the severity of parkinsonism and the latency to the onset of dyskinesias, at both multivariate analysis of cross sectional data and during the prospective follow-up of patients. The *post hoc* analyses of the STRIDE-PD trial are consistent with our observations, as the severity of motor symptoms had no predictive role for dyskinesias ([@awu195-B50]). Interestingly, [@awu195-B12] similarly reported in their pivotal study on levodopa that 'the most severe involuntary movements were induced among the patients whose disease had the longest duration, not necessarily among those with the most severe disease'. This discrepancy might be explained considering that patients with different degrees of neuronal loss may present with comparable severity of motor symptoms, as compensatory mechanisms may modulate the length of the pre-motor stage of Parkinson's disease considerably ([@awu195-B16]). In particular, younger age at onset is associated with better presynaptic and postsynaptic compensatory mechanisms aimed at keeping normal striatal dopamine. Thus, early-onset patients may tolerate greater severity of substantia nigra pars compacta neuronal loss before dopamine levels decrease below the estimated threshold for the first motor symptoms to appear ([@awu195-B16]). Therefore, it could be argued that the higher risk of dyskinesias associated with younger age at Parkinson's disease onset, consistently described so far ([@awu195-B34]; [@awu195-B50]) and confirmed in the present study, might be due to a greater extent of neuronal loss in patients with similar severity of motor symptoms. Overall, these data support the idea that it is the duration of Parkinson's disease rather than the severity of motor symptoms that is closely associated with the extent of neuronal loss. In turn, it is the extent of substantia nigra pars compacta neuronal loss that causes the decrease in striatal dopamine levels that predisposes to the development of motor complications once a patient with Parkinson's disease is exposed to levodopa. Nevertheless, preclinical ([@awu195-B26]) and clinical ([@awu195-B38]) studies show that similar extension of neuronal loss may lead to involuntary movements in some individuals and not in others after exposure to similar levodopa doses, suggesting that individual predisposition is likely to play a role in addition to disease-related variables, including genetic factors (reviewed in [@awu195-B40]). Further evidence is provided by the Ghanaian patient who developed peak-dose dyskinesias after the first-ever levodopa intake despite her mild disease severity, which is in contrast to the relatively delayed appearance of dykinesias in patients with more severe motor symptoms. This paradigmatic case supports the hypothesis that the induction of levodopa-induced dyskinesias (defined as 'priming' process) does not require chronic dopaminergic treatment and brain sensitization ([@awu195-B13]; [@awu195-B29]), but may occur even after the first-ever dose of levodopa in a dopamine-depleted brain ([@awu195-B48]). Nigrostriatal degeneration has generally been considered to be mandatory in the pathogenesis of dyskinesias in view of the absence of dyskinesias in animals or humans with intact dopamine system despite long-term exposure to levodopa ([@awu195-B5]; [@awu195-B33]), including patients with DOPA-responsive dystonia due to *GCH1* mutations ([@awu195-B49]; [@awu195-B61]). However, levodopa-induced dyskinesias may be generated under extreme conditions even when basal ganglia are normal, as shown in animals and humans with preserved substantia nigra pars compacta neuronal density that received very high doses of levodopa ([@awu195-B31]; [@awu195-B60]; [@awu195-B33]). On the other hand, dyskinesias may develop in the absence of substantia nigra pars compacta neuronal loss even after exposure to low levodopa doses in the dopamine-depleted brain of patients with tyrosine hydroxylase deficiency, most likely via postsynaptic dopamine receptor super-sensitivity ([@awu195-B6]; [@awu195-B4]; [@awu195-B54]). Taken as a whole, these data suggest that striatal dopamine levels and levodopa dose are inversely related in the equation predicting dyskinesias, in a continuum that does not include the duration of levodopa therapy. Age at onset and individual genetically-inherited predisposing factors have a modulatory effect ([@awu195-B40]).

This study has some limitations that should be acknowledged. First, we used a control Parkinson's disease population with a different genetic and environmental background ([@awu195-B9], [@awu195-B10]). Therefore, we cannot definitely exclude the possibility that Parkinson's disease in black Africans may have a different phenotype and response to levodopa and further studies are needed to confirm the present findings without the bias related to the assessment of different populations. Nevertheless, we found that major demographic and clinical characteristics 5 years after onset were overall comparable, suggesting that potential differences related to the geographical setting did not play a substantial role in the current findings. In particular, our extensive analysis did not reveal any significant difference in terms of mean age at onset, frequency of major non-motor features, and severity of motor symptoms, including response to acute levodopa challenge, non-levodopa-responsive motor symptoms, activities of daily living and progression to advanced disease stages. As the awareness of the disease and the skills of local doctors are progressively increasing in several sub-Saharan African countries, the disease is diagnosed at earlier stages and levodopa therapy started accordingly. Therefore, it is conceivable that in the near future it will be possible to perform a direct comparison between patients with an early-start compared to those with a delayed-start of levodopa. Second, the different access to medications between the two populations forced us to add a control subgroup of patients with Parkinson's disease who had never been exposed to dopamine agonists or COMT inhibitors and thus complicated the design of study analyses. Finally, this study was not designed as a community-based trial and inclusion bias might have occurred. In the attempt to make the study cohort as representative as possible of the general Parkinson's disease population in the sub-Saharan African region, we conducted a long-term naturalistic study observing outpatients consecutively referred not only to two neurology clinics in large cities of densely populated regions, but also to a small clinic in a rural area of the country. Nonetheless, the higher frequency of patients presenting with a tremor-dominant phenotype reasonably reflects the low awareness of Parkinson's disease that still induces most doctors and patients to place stronger emphasis on resting tremor as the 'cardinal symptom' leading to suspect Parkinson's disease (as gait and balance disturbances are generally attributed to normal ageing) so that non-tremor-dominant subtypes are likely to be under-represented. This observation underlines further the need to promote educational initiatives in developing countries ([@awu195-B47]). The different phenotype at presentation might have had a confounding effect on clinical variables, including the risk of motor complications. It has been recently suggested that the tremor-dominant presenting phenotype may be a negative predictor of dyskinesias ([@awu195-B36]; [@awu195-B65]). In a clinicopathological study, the onset of dyskinesias was delayed by ∼2 years in patients presenting with a tremor-dominant motor phenotype compared to those with a non-tremor phenotype (although this difference was not statistically significant, [@awu195-B57]). Accordingly, we might assume that, if the Ghanaian cohort had had a similar proportion of patients with non-tremor-dominant phenotype to the Italian control population, the main finding of the present study would have been strengthened even further, as the rate of motor complications would have been expected to be higher and their appearance even earlier than what we found. Overall, we believe that our naturalistic case-control study including a matched control population from a Western country was the only possible way to provide conclusive answers about the relationship between levodopa therapy and disease progression in the pathophysiology of motor complications, overcoming the limitations of previous studies.

Conclusion
==========

The present study provides evidence that motor fluctuations and dyskinesias are not associated with the duration of exposure to levodopa therapy, but rather to disease progression itself. Therefore, there is no reason to delay the initiation of adequate levodopa therapy in patients with Parkinson's disease. In contrast with past drug trials, recent experimental studies suggest that the best therapeutic option to delay the molecular changes in gene expression, synaptic morphology and abnormal corticostriatal connectivity associated with dyskinesias may be early initiation of levodopa treatment ([@awu195-B41]). We emphasize the importance of considering the pharmacokinetic properties of levodopa and recommend (i) to adjust the individual levodopa dose regimen per kilogram of body weight to reduce the risk of dyskinesias ([@awu195-B64]; [@awu195-B58]; [@awu195-B50]); and (ii) to consider the potential benefits of dietary protein redistribution during the daytime to minimize levodopa requirement and improve the control of motor fluctuations ([@awu195-B43]; [@awu195-B7]). Further studies are needed to better understand the natural course of Parkinson's disease without the confounding effect of medications, and the pathophysiology of motor and non-motor symptoms. Whether the answers will come from Africa, time will tell.
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UPDRS

:   Unified Parkinson's Disease Rating Scale

[^1]: See Lang (doi:10.1093/brain/awu212) for a scientific commentary on this article.

[^2]: ^a^Family history of Parkinson's disease in Ghana could not be directly documented by a neurologist in the majority of cases.

[^3]: ^a^Matching criteria.

[^4]: ^b^Calculated on the subgroup of patients on levodopa therapy.

[^5]: ^c^Tremor at rest is defined as the sum of UPDRS III items 20, wheras axial symptoms as the sum of items 27 + 28 + 29 + 30.

[^6]: \*By Student's *t*-test or Fischer's exact test as appropriate. Data are reported as mean (SD), unless otherwise specified.

[^7]: Data are reported as mean (SD) \[range\], unless otherwise specified.

[^8]: ^a^ Matching criteria.

[^9]: *P*-values were computed using Student's *t*-test or Fischer's exact test as appropriate (†) or one-way ANOVA (**‡**; *post hoc* comparison of means were performed using Sheffe's test: ^§^*P* \< 0.05 and ^§§^*P* \< 0.01 for comparisons between 'Non-Fluctuators' versus 'Fluctuators'; **^\#^***P* \< 0.05 and ^\#\#^*P* \< 0.01 for comparisons between Ghanaian 'Fluctuators' versus Italian 'Fluctuators'). Significant values (P\<0.05) are in bold.

[^10]: ^a^Capacity to correctly classify positive cases as quantified by the area under the receiver operating characteristic curve (AUC): the closer to 1, the better the model performance.

[^11]: ^b^A, levodopa daily dose (mg/kg); B, duration of levodopa at occurrence of complications (years); C, disease duration at occurrence of complications (years); D, disease severity (OFF-state UPDRS part III score).

[^12]: ^c^The model including the set of variables A + B + C + D could not be performed due to high collinearity (Pearson\'s \> 40.5) between disease severity and levodopa daily dose.

[^13]: ^d,e^Best predictive models for motor complications were those including Levodopa dose, duration of levodopa and duration of disease at their onset. Significant values (p \< 0.05) are in bold.
